MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$20,207K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-25,579 -52,293
Depreciation and amortization
40 86
Unrealized foreign currency gain
0 0
Stock-based compensation
3,614 3,941
Non-cash lease expense
48 108
Change in fair value of tranche rights
0 0
Fees expensed as part of january 2024 financing
0 0
Other current assets and prepaid expenses
-384 429
Accounts payable
-31 -896
Accrued expenses
1,428 3,447
Operating lease liabilities
-50 -118
Other liabilities
6 -231
Net cash used in operating activities
-20,140 -46,385
Purchases of property and equipment
67 83
Net cash used in investing activities
-67 -83
Proceeds from offering, net of issuance costs-May2025PIPETransaction
0 60,661
Proceeds from offering, net of issuance costs-April2025PIPETransaction
0 4,734
Proceeds from public offering of common stock through at the market sales agreement, net
0 0
Proceeds from offering, net of issuance costs-January2024PIPETransaction
0 0
Proceeds from shares issued in connection with the company's employee stock purchase plan
0 123
Net cash provided by financing activities
0 65,518
Effect of exchange rate changes on cash and cash equivalents
29 592
Net change in cash and cash equivalents
-20,178 19,642
Cash and cash equivalents at beginning of period
35,668 -
Cash and cash equivalents at end of period
35,132 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IMMUNIC, INC. (IMUX)

IMMUNIC, INC. (IMUX)